Sanofi licenses NK cells of Kiadis to boost the efficacy
Sanofi has licensed the natural killer (NK) cells from Kiadis Pharma for use in combination with its multiple myeloma drug Sarclisa. The deal worth of USD 986 million gives the global rights to Sanofi for therapies that could lessen an efficacy-limiting shortcoming of anti-CD38 antibodies.
Sarclisa and Darzalex, the antibody of Johnson & Johnson, target CD38 that is a glycoprotein found at high levels on multiple myeloma cells and relatively low levels on healthy lymphoid and myeloid cells. The difference in expression levels is significant enough for the anti-CD38 antibodies to enhance results i...